Metastatic gastric cancer: medical treatment

Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Castellano, J. [verfasserIn] Guimbaud, R. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	Metastatic gastric cancer Systemic chemotherapy Targeted therapies

Übergeordnetes Werk:	Enthalten in: Oncologie - Paris : Springer France, 2004, 15(2013), 3-4 vom: März, Seite 161-168
Übergeordnetes Werk:	volume:15 ; year:2013 ; number:3-4 ; month:03 ; pages:161-168

Links:	Volltext

DOI / URN:	10.1007/s10269-013-2268-8

Katalog-ID:	SPR009303219

Internformat


LEADER	01000caa a22002652 4500
001	SPR009303219
003	DE-627
005	20230519094839.0
007	cr uuu---uuuuu
008	201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10269-013-2268-8 \|2 doi
035			\|a (DE-627)SPR009303219
035			\|a (SPR)s10269-013-2268-8-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
082	0	4	\|a 610 \|q ASE
084			\|a 44.81 \|2 bkl
100	1		\|a Castellano, J. \|e verfasserin \|4 aut
245	1	0	\|a Metastatic gastric cancer: medical treatment
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.
650		4	\|a Metastatic gastric cancer \|7 (dpeaa)DE-He213
650		4	\|a Systemic chemotherapy \|7 (dpeaa)DE-He213
650		4	\|a Targeted therapies \|7 (dpeaa)DE-He213
700	1		\|a Guimbaud, R. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Oncologie \|d Paris : Springer France, 2004 \|g 15(2013), 3-4 vom: März, Seite 161-168 \|w (DE-627)38748213X \|w (DE-600)2145843-1 \|x 1765-2839 \|7 nnns
773	1	8	\|g volume:15 \|g year:2013 \|g number:3-4 \|g month:03 \|g pages:161-168
856	4	0	\|u https://dx.doi.org/10.1007/s10269-013-2268-8 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_120
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_206
912			\|a GBV_ILN_267
912			\|a GBV_ILN_293
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
936	b	k	\|a 44.81 \|q ASE
951			\|a AR
952			\|d 15 \|j 2013 \|e 3-4 \|c 03 \|h 161-168

Indexfelder

author_variant	j c jc r g rg
matchkey_str	article:17652839:2013----::eattcaticnemd
hierarchy_sort_str	2013
bklnumber	44.81
publishDate	2013
allfields	10.1007/s10269-013-2268-8 doi (DE-627)SPR009303219 (SPR)s10269-013-2268-8-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Castellano, J. verfasserin aut Metastatic gastric cancer: medical treatment 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies. Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Enthalten in Oncologie Paris : Springer France, 2004 15(2013), 3-4 vom: März, Seite 161-168 (DE-627)38748213X (DE-600)2145843-1 1765-2839 nnns volume:15 year:2013 number:3-4 month:03 pages:161-168 https://dx.doi.org/10.1007/s10269-013-2268-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 44.81 ASE AR 15 2013 3-4 03 161-168
spelling	10.1007/s10269-013-2268-8 doi (DE-627)SPR009303219 (SPR)s10269-013-2268-8-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Castellano, J. verfasserin aut Metastatic gastric cancer: medical treatment 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies. Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Enthalten in Oncologie Paris : Springer France, 2004 15(2013), 3-4 vom: März, Seite 161-168 (DE-627)38748213X (DE-600)2145843-1 1765-2839 nnns volume:15 year:2013 number:3-4 month:03 pages:161-168 https://dx.doi.org/10.1007/s10269-013-2268-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 44.81 ASE AR 15 2013 3-4 03 161-168
allfields_unstemmed	10.1007/s10269-013-2268-8 doi (DE-627)SPR009303219 (SPR)s10269-013-2268-8-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Castellano, J. verfasserin aut Metastatic gastric cancer: medical treatment 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies. Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Enthalten in Oncologie Paris : Springer France, 2004 15(2013), 3-4 vom: März, Seite 161-168 (DE-627)38748213X (DE-600)2145843-1 1765-2839 nnns volume:15 year:2013 number:3-4 month:03 pages:161-168 https://dx.doi.org/10.1007/s10269-013-2268-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 44.81 ASE AR 15 2013 3-4 03 161-168
allfieldsGer	10.1007/s10269-013-2268-8 doi (DE-627)SPR009303219 (SPR)s10269-013-2268-8-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Castellano, J. verfasserin aut Metastatic gastric cancer: medical treatment 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies. Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Enthalten in Oncologie Paris : Springer France, 2004 15(2013), 3-4 vom: März, Seite 161-168 (DE-627)38748213X (DE-600)2145843-1 1765-2839 nnns volume:15 year:2013 number:3-4 month:03 pages:161-168 https://dx.doi.org/10.1007/s10269-013-2268-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 44.81 ASE AR 15 2013 3-4 03 161-168
allfieldsSound	10.1007/s10269-013-2268-8 doi (DE-627)SPR009303219 (SPR)s10269-013-2268-8-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Castellano, J. verfasserin aut Metastatic gastric cancer: medical treatment 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies. Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Enthalten in Oncologie Paris : Springer France, 2004 15(2013), 3-4 vom: März, Seite 161-168 (DE-627)38748213X (DE-600)2145843-1 1765-2839 nnns volume:15 year:2013 number:3-4 month:03 pages:161-168 https://dx.doi.org/10.1007/s10269-013-2268-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 44.81 ASE AR 15 2013 3-4 03 161-168
language	English
source	Enthalten in Oncologie 15(2013), 3-4 vom: März, Seite 161-168 volume:15 year:2013 number:3-4 month:03 pages:161-168
sourceStr	Enthalten in Oncologie 15(2013), 3-4 vom: März, Seite 161-168 volume:15 year:2013 number:3-4 month:03 pages:161-168
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Metastatic gastric cancer Systemic chemotherapy Targeted therapies
dewey-raw	610
isfreeaccess_bool	false
container_title	Oncologie
authorswithroles_txt_mv	Castellano, J. @@aut@@ Guimbaud, R. @@aut@@
publishDateDaySort_date	2013-03-01T00:00:00Z
hierarchy_top_id	38748213X
dewey-sort	3610
id	SPR009303219
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009303219</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519094839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10269-013-2268-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009303219</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10269-013-2268-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castellano, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Metastatic gastric cancer: medical treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastatic gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systemic chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted therapies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guimbaud, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Oncologie</subfield><subfield code="d">Paris : Springer France, 2004</subfield><subfield code="g">15(2013), 3-4 vom: März, Seite 161-168</subfield><subfield code="w">(DE-627)38748213X</subfield><subfield code="w">(DE-600)2145843-1</subfield><subfield code="x">1765-2839</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3-4</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:161-168</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10269-013-2268-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">3-4</subfield><subfield code="c">03</subfield><subfield code="h">161-168</subfield></datafield></record></collection>
author	Castellano, J.
spellingShingle	Castellano, J. ddc 610 bkl 44.81 misc Metastatic gastric cancer misc Systemic chemotherapy misc Targeted therapies Metastatic gastric cancer: medical treatment
authorStr	Castellano, J.
ppnlink_with_tag_str_mv	@@773@@(DE-627)38748213X
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1765-2839
topic_title	610 ASE 44.81 bkl Metastatic gastric cancer: medical treatment Metastatic gastric cancer (dpeaa)DE-He213 Systemic chemotherapy (dpeaa)DE-He213 Targeted therapies (dpeaa)DE-He213
topic	ddc 610 bkl 44.81 misc Metastatic gastric cancer misc Systemic chemotherapy misc Targeted therapies
topic_unstemmed	ddc 610 bkl 44.81 misc Metastatic gastric cancer misc Systemic chemotherapy misc Targeted therapies
topic_browse	ddc 610 bkl 44.81 misc Metastatic gastric cancer misc Systemic chemotherapy misc Targeted therapies
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Oncologie
hierarchy_parent_id	38748213X
dewey-tens	610 - Medicine & health
hierarchy_top_title	Oncologie
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)38748213X (DE-600)2145843-1
title	Metastatic gastric cancer: medical treatment
ctrlnum	(DE-627)SPR009303219 (SPR)s10269-013-2268-8-e
title_full	Metastatic gastric cancer: medical treatment
author_sort	Castellano, J.
journal	Oncologie
journalStr	Oncologie
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	161
author_browse	Castellano, J. Guimbaud, R.
container_volume	15
class	610 ASE 44.81 bkl
format_se	Elektronische Aufsätze
author-letter	Castellano, J.
doi_str_mv	10.1007/s10269-013-2268-8
dewey-full	610
author2-role	verfasserin
title_sort	metastatic gastric cancer: medical treatment
title_auth	Metastatic gastric cancer: medical treatment
abstract	Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.
abstractGer	Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.
abstract_unstemmed	Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_206 GBV_ILN_267 GBV_ILN_293 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2055 GBV_ILN_2059 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305
container_issue	3-4
title_short	Metastatic gastric cancer: medical treatment
url	https://dx.doi.org/10.1007/s10269-013-2268-8
remote_bool	true
author2	Guimbaud, R.
author2Str	Guimbaud, R.
ppnlink	38748213X
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s10269-013-2268-8
up_date	2024-07-04T01:31:47.894Z
_version_	1803610182543998976
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009303219</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519094839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10269-013-2268-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009303219</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10269-013-2268-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Castellano, J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Metastatic gastric cancer: medical treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Specific treatment of the metastatic gastric cancer is based on systemic chemotherapy. Among numerous schedules, polychemotherapies based on 5-FU and cisplatin (± anthracyclin), as CF and ECF, remain international standards. Over the ten last years, new cytotoxics proved to be efficient as taxanes, oxaliplatine, oral 5-FU (capecitabine) and irinotecan. New schedules of chemotherapy were validated, allowing either a (moderate) benefit in survival or an equivalent survival with better tolerance. Anyway median survival remains inferior to 12 months. Targeted therapies are promising. Today, only anti-HER2 therapy (traztuzumab in association with 5-FU and cisplatin), limited to gastric cancer overexpressing HER2 (20% of cases), is validated in clinical practice. Phase III studies testing anti-EGFR, and at less extent anti-VEGF, failed to deliver satisfactory results. Nonetheless, numerous studies are ongoing and could be promising, for instance regarding anti-cMet therapies. Finally, fewstudies have investigated global therapeutic strategies. But the efficiency of a 2nd line chemotherapy (with irinotecan or taxane) is now well established by phase III studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastatic gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systemic chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted therapies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guimbaud, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Oncologie</subfield><subfield code="d">Paris : Springer France, 2004</subfield><subfield code="g">15(2013), 3-4 vom: März, Seite 161-168</subfield><subfield code="w">(DE-627)38748213X</subfield><subfield code="w">(DE-600)2145843-1</subfield><subfield code="x">1765-2839</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3-4</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:161-168</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10269-013-2268-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">3-4</subfield><subfield code="c">03</subfield><subfield code="h">161-168</subfield></datafield></record></collection>
score	7.39935

Nicht das Richtige dabei?

Schreiben Sie uns!

Metastatic gastric cancer: medical treatment

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?